Podcast

Huntsman Homes in on the Integration of Precision Medicine in Oncology

Author(s):

In our exclusive interview, Dr. Huntsman discusses the elements of precision medicine that have contributed to its growth in the field of oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.

Welcome to OncLive On Air! I’m your host today, Jessica Hergert.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, we had the pleasure of speaking with David Huntsman, MD, FRCPC, FCCMG, the Dr. Chew Wei Memorial Professor of Gynaecologic Oncology, Canada Research Chair in Molecular and Genomic Pathology, professor in the Departments of Pathology and Laboratory Medicine and Obstetrics and Gynaecology at the University of British Columbia, co-founder and director of OVCARE, and chief medical office of Canexia Health, to discuss the growth of precision medicine across oncology.

In our exclusive interview, Huntsman discussed the elements of precision medicine that have contributed to its growth in the field of oncology, some of the setbacks regarding its integration, and areas of research that have the potential to propel precision medicine to the next tier of scientific discovery and application.

Related Videos
Eunice S. Wang, MD
Marcella Ali Kaddoura, MD
Kathleen N. Moore, MD, MS
Kathleen N. Moore, MD, MS
Mary B. Beasley, MD, discusses molecular testing challenges in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the multidisciplinary management of NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of pathologists in molecular testing in non–small cell lung cancer and pancreatic cancer.
Mary B. Beasley, MD, discusses the role of RNA and other testing considerations for detecting NRG1 and other fusions in solid tumors.
Mary B. Beasley, MD, discusses the prevalence of NRG1 fusions in non–small cell lung cancer and pancreatic cancer.
Cedric Pobel, MD